Cita APA

S., P., J.-L., P., U., D., M., D., S., P., M., R., . . . R., C. (2022). Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.

Citación estilo Chicago

S., Peters, et al. Consolidation Nivolumab and Ipilimumab Versus Observation in Limited-disease Small-cell Lung Cancer After Chemo-radiotherapy – Results From the Randomised Phase II ETOP/IFCT 4-12 STIMULI Trial. 2022.

Cita MLA

S., Peters, et al. Consolidation Nivolumab and Ipilimumab Versus Observation in Limited-disease Small-cell Lung Cancer After Chemo-radiotherapy – Results From the Randomised Phase II ETOP/IFCT 4-12 STIMULI Trial. 2022.